Equities
Health CareMedical Equipment and Services
  • Price (USD)126.48
  • Today's Change1.89 / 1.52%
  • Shares traded728.23k
  • 1 Year change+13.79%
  • Beta1.0436
Data delayed at least 15 minutes, as of Sep 19 2024 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Revvity, Inc. is a provider of health science solutions, technologies, and services, which delivers workflows from discovery to development, and diagnosis to cure. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards the life sciences market. The Life Sciences Segment applications include MicroBeta, The MuviCyte live-cell imaging system, The Signals Image Artist, The VICTOR Nivo multimode plate reader benchtop system, The EnSight multimode plate reader benchtop system, BioLegend LEGENDplex bead-based reagents, and The Quantum GX2 system. Its Diagnostics segment develops diagnostics, tools, and applications focused on clinically oriented customers, within the reproductive health, immunodiagnostics, and applied genomics markets. It offers instruments, reagents, assay platforms and software to hospitals, and medical labs. It is focused on reproductive health, immunodiagnostics, and emerging market diagnostics.

  • Revenue in USD (TTM)2.71bn
  • Net income in USD197.34m
  • Incorporated1947
  • Employees11.50k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Henry Schein, Inc.12.49bn352.00m9.18bn25.00k26.792.6214.550.73532.712.7195.9827.641.294.888.25499,480.003.586.095.9710.4431.6330.042.784.400.8966.850.33330.00-2.445.55-22.68-0.145621.27--
Bio Rad Laboratories Inc2.56bn-1.33bn9.42bn8.03k--1.42--3.68-47.03-47.0389.18240.390.23661.495.47319,128.80-12.249.08-12.879.6054.0255.55-51.7341.974.630.16530.15040.00-4.673.1382.43--3.83--
Globus Medical Inc2.24bn40.68m9.42bn5.00k234.442.3734.994.210.29680.296817.0229.380.62071.635.25447,306.001.136.901.307.4559.6571.731.8214.051.45455.560.0980.0053.3417.08-35.39-4.725.57--
Bruker Corp3.12bn352.10m10.11bn9.71k27.805.6520.413.242.402.4021.2411.820.63931.475.90321,386.607.218.389.5911.4050.0849.8511.2811.390.724443.060.54199.8117.149.3644.0318.9116.794.56
Teleflex Inc3.01bn264.76m11.38bn14.50k43.172.5021.853.785.595.5763.5496.760.41962.096.85207,437.103.695.864.006.4255.8654.438.8014.621.447.140.273715.846.573.97-1.4712.732.510.00
Revvity Inc2.71bn197.34m15.37bn11.50k78.011.9524.535.671.601.3721.9063.800.19592.894.42235,499.601.434.761.595.3955.2657.197.2915.341.986.890.32996.52-16.95-0.1982-64.99-5.28-2.690.00
Insulet Corp1.87bn395.30m16.55bn3.00k43.6216.5835.168.845.415.4124.5314.240.7111.386.25624,233.3015.012.7118.153.1469.0065.8121.114.282.7187.970.58330.0030.0224.664,384.78128.77-7.63--
Avantor Inc6.83bn360.20m18.40bn14.50k51.103.3824.172.700.52950.529510.038.000.5305.375.82470,731.002.802.973.173.3533.7133.445.285.061.053.070.48480.00-7.263.51-51.52--31.17--
Align Technology, Inc.3.94bn447.03m18.90bn21.61k42.915.0332.204.795.905.9052.0350.310.6414.164.09182,455.407.2716.3410.9624.1469.8271.7211.3423.161.06--0.000.003.4214.4523.092.15-4.46--
Hologic Inc3.99bn701.50m18.98bn6.99k27.893.8318.774.762.932.9316.5921.330.43752.646.06570,472.107.7011.408.6413.3855.4160.2917.5920.953.32709.770.34080.00-17.124.61-64.98--7.30--
Waters Corp2.88bn595.69m19.79bn7.90k33.2114.0125.136.8810.0410.0448.4623.790.63942.194.41364,118.2013.2419.7716.0425.2959.6858.4520.7123.381.428.740.58690.00-0.52294.09-9.261.534.72--
Baxter International Inc15.00bn-157.00m20.09bn60.00k--2.6318.101.34-0.30664.8729.4814.980.55343.245.73249,950.00-0.54620.1942-0.70190.233336.4838.20-0.98690.36740.91474.250.6261,398.942.125.9497.15--0.9829.71
Illumina Inc4.43bn-3.04bn20.86bn10.59k--14.50--4.71-19.18-19.1827.949.030.49612.866.26418,224.80-34.09-6.20-45.61-7.2862.0066.39-68.71-15.480.859614.070.6087---1.756.2173.64---7.91--
Zimmer Biomet Holdings Inc7.52bn997.10m21.64bn18.00k22.151.7111.032.884.804.8036.2262.180.35150.91415.40418,050.004.662.215.402.5271.7871.2513.277.280.6297.510.31438.906.55-1.40252.86--9.440.00
Data as of Sep 19 2024. Currency figures normalised to Revvity Inc's reporting currency: US Dollar USD

Institutional shareholders

57.31%Per cent of shares held by top holders
HolderShares% Held
T. Rowe Price Investment Management, Inc.as of 30 Jun 202418.01m14.61%
The Vanguard Group, Inc.as of 30 Jun 202413.53m10.97%
Select Equity Group LPas of 30 Jun 20247.37m5.98%
Janus Henderson Investors US LLCas of 30 Jun 20246.19m5.02%
BlackRock Fund Advisorsas of 30 Jun 20246.12m4.97%
SSgA Funds Management, Inc.as of 30 Jun 20245.16m4.19%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 20245.15m4.18%
Mitsubishi UFJ Asset Management Co., Ltd.as of 30 Jun 20243.24m2.63%
Capital Research & Management Co. (Global Investors)as of 30 Jun 20243.06m2.48%
Geode Capital Management LLCas of 30 Jun 20242.84m2.30%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.